Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1966;34:856-864

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WESSLER, S.
Right arrow Articles by GASTON, L. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WESSLER, S.
Right arrow Articles by GASTON, L. W.

(Circulation. 1966;34:856.)
© 1966 American Heart Association, Inc.


Anticoagulant Therapy in Coronary Artery Disease

STANFORD WESSLER M.D.1 LAMONT W. GASTON M.D.1

1 From the Department of Medicine, Washington University School of Medicine and The Jewish Hospital of St. Louis, St. Louis, Missouri.

Information available at the present time allows the following conclusions to be drawn:

1. Anticoagulant therapy is clearly effective in treating and preventing venous thrombosis and pulmonary emboli.

2. If used in the treatment of acute myocardial infarction, anticoagulant drugs may salvage 3 to 4% of the treated population. This small gain is probably achieved by the prevention of thromboembolic episodes. While only a small percentage of patients are benefited, the actual number of persons salvaged is relatively great because of the large size of the population at risk. In the considerable majority of treated patients who do not benefit from coumarin drugs, the therapy need do no harm, if proper safeguards are employed in the selection of patients and the administration and laboratory control of the drug.

3. In long-term therapy of patients who have recovered from acute myocardial infarction, it appears that men, especially below age 60, may be helped for the first 1 or 2 years after infarction.

4. More data are required to evaluate the role of anticoagulant treatment in patients with angina pectoris or coronary insufficiency. For the present, the physician may reasonably be influenced in the use of anticoagulant therapy by the recent onset of symptoms, the patient's age, and the family history.

5. Although appropriately controlled studies are lacking, it appears as though patients with peripheral emboli secondary to coronary artery disease may be benefited by anticoagulant therapy.




This article has been cited by other articles:


Home page
JAMAHome page
S. Wessler and L. V. Avioli
Anticoagulants in Treatment of Patients With Hip Fracture
JAMA, April 8, 1968; 204(2): 140 - 144.
[Abstract] [PDF]


Home page
JAMAHome page
CURRENT GUIDELINES TO ANTICOAGULANT THERAPY
JAMA, September 11, 1967; 201(11): 877 - 878.
[Abstract] [PDF]